Minerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Other Events
Item8.01
| Other Events |
On May15, 2017, Minerva Neurosciences, Inc. (the Company) issued
a press release providing details of the Companys MIN-101
end-of-Phase 2 meeting with the U.S. Food and Drug
Administration, and a press release providing an update on the
Companys MIN-101 Phase 3 design and development strategy. A copy
of the above referenced press releases are filed as Exhibit 99.1
and Exhibit 99.2 to this Current Report on Form 8-K.
The Company is also filing the investor presentation slides
attached as Exhibit 99.3 to this Current Report on Form 8-K which
the Company may use from time to time with investors and
analysts. The presentation will also be available in the investor
relations section of the Companys website.
| Item9.01. | Financial Statements and Exhibits |
| (d) | Exhibits |
|
Exhibit No. |
Description |
|
|
99.1 |
Press Release of the Company dated May 15, 2017 | |
|
99.2 |
Press Release of the Company dated May 15, 2017 | |
|
99.3 |
Presentation of the Company dated May 16, 2017 |
About Minerva Neurosciences, Inc. (NASDAQ:NERV)
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein. Minerva Neurosciences, Inc. (NASDAQ:NERV) Recent Trading Information
Minerva Neurosciences, Inc. (NASDAQ:NERV) closed its last trading session up +0.50 at 7.50 with 146,047 shares trading hands.
